waldenström macroglobulinemia ˈvældənstrɒm ˌmækroʊˌɡlɒbjəlɪˈniːmiə valdənstrom us also ˈvɑːldənstrɛm vahldənstrem type cancer affecting two types b cells lymphoplasmacytoid cells plasma cells cell types white blood cells characterized high levels circulating antibody immunoglobulin igm made secreted cells involved disease waldenström macroglobulinemia indolent lymphoma ie one tends grow spread slowly type lymphoproliferative disease shares clinical characteristics indolent nonhodgkin commonly classified form plasma cell dyscrasia similar plasma cell dyscrasias example lead multiple myeloma waldenström macroglobulinemia commonly preceded two clinically asymptomatic progressively premalignant phases igm monoclonal gammopathy undetermined significance smoldering waldenström macroglobulinemia waldenström macroglobulinemia spectrum dysplasias differs spectrums plasma cell dyscrasias involves aberrant plasma cells also aberrant lymphoplasmacytoid cells involves igm plasma dyscrasias involve antibody waldenström macroglobulinemia rare disease cases per year united states occurs frequently older disease incurable treatable indolent nature many patients able lead active lives treatment required may experience years symptomfree signs symptoms waldenström macroglobulinemia include weakness fatigue weight loss chronic oozing blood nose peripheral neuropathy occurs patients enlargement lymph nodes spleen andor liver present possible signs symptoms include blurring loss vision headache rarely stroke comacitation needed waldenström macroglobulinemia characterized uncontrolled clonal proliferation terminally differentiated b lymphocytes commonly associated mutations based wholegenome sequencing patients somatic mutation patients somatic mutation mutations cause symptomatic hyperviscosity syndrome high bone marrow activity characteristic however mutation associated splenomegaly high platelet counts different response therapy questioning relevance treating association demonstrated locus chromosome two threefold increased risk waldenström macroglobulinemia people personal history autoimmune diseases autoantibodies particularly elevated risk associated liver inflammation human immunodeficiency virus genetic factors firstdegree relatives waldenström macroglobulinemia patients shown highly increased risk also developing also evidence suggest environmental factors including exposure farming pesticides wood dust organic solvents may influence development waldenström although believed sporadic disease studies shown increased susceptibility within families indicating genetic mutation gene found occur frequently waldenström macroglobulinemia cells show minimal changes cytogenetic gene expression studies mirna signature however differs normal counterpart therefore believed epigenetic modifications play crucial role comparative genomic hybridization identified following chromosomal abnormalities deletions gains following signalling pathways implicated protein src tyrosine kinase overexpressed waldenström macroglobulinemia cells compared control b inhibition src arrests cell cycle phase little effect survival waldenström macroglobulinemia normal cells micrornas involved regulates proliferation growth waldenström macroglobulinemia cells vitro vivo inhibiting mapkerk nfκb pathwayscitation needed waldenström macroglobulinemia cells histone deacetylases histonemodifying genes bone marrow tumour cells express following antigen targets igm core protein symptoms including blurring loss vision headache rarely stroke coma due effects igm paraprotein may cause autoimmune phenomena cryoglobulinemia symptoms waldenström macroglobulinemia due hyperviscosity syndrome present attributed igm monoclonal protein molecules increasing viscosity blood forming aggregates binding water carbohydrate component interaction blood diagnosis waldenström macroglobulinemia depends significant monoclonal igm spike evident blood tests malignant cells consistent disease bone marrow biopsy blood tests show level igm blood presence proteins tumor markers key signs waldenström macroglobulinemia bone marrow biopsy provides sample bone marrow usually lower back pelvis bone sample extracted needle examined microscope pathologist identifies particular lymphocytes indicate waldenström macroglobulinemia flow cytometry may used examine markers cell surface inside additional tests computed tomography ct cat scan may used evaluate chest abdomen pelvis particularly swelling lymph nodes liver spleen skeletal survey help distinguish waldenström macroglobulinemia multiple anemia occurs patients waldenström macroglobulinemia low white blood cell count low platelet count blood may observed low level neutrophils specific type white blood cell may also found individuals waldenström chemistry tests include lactate dehydrogenase ldh levels uric acid levels erythrocyte sedimentation rate esr kidney liver function total protein levels albumintoglobulin ratio esr uric acid level may elevated creatinine occasionally elevated electrolytes occasionally abnormal high blood calcium level noted approximately patients ldh level frequently elevated indicating extent waldenström tissue involvement rheumatoid factor cryoglobulins direct antiglobulin test cold agglutinin titre results positive microglobulin creactive protein test results specific waldenström macroglobulinemia microglobulin elevated proportion tumor mass coagulation abnormalities may present prothrombin time activated partial thromboplastin time thrombin time fibrinogen tests performed platelet aggregation studies optional serum protein electrophoresis results indicate evidence monoclonal spike establish spike igm component betatogamma mobility highly suggestive waldenström macroglobulinemia immunoelectrophoresis immunofixation studies help identify type immunoglobulin clonality light chain monoclonality quantitation paraprotein highresolution electrophoresis serum urine immunofixation recommended help identify characterize monoclonal igm paraprotein light chain monoclonal protein usually kappa light chain times patients waldenström macroglobulinemia may exhibit one protein plasma viscosity must measured results characterization studies urinary immunoglobulins indicate light chains bence jones protein usually kappa type found urine urine collections concentrated bence jones proteinuria observed approximately patients exceeds gd approximately patients patients findings peripheral neuropathy nerve conduction studies antimyelin associated glycoprotein serologycitation needed criteria diagnosis waldenström macroglobulinemia include single accepted treatment waldenström marked variation clinical outcome due gaps knowledge diseases molecular basis objective response rates high complete response rates low medication ibrutinib targets mutation induced activation brutons tyrosine cohort study previously treated patients ibrutinib induced responses patients years patients progression disease based study food drug administration approved ibrutinib use waldenström macroglobulinemia different treatment flowcharts needed patients waldenström macroglobulinemia higher risk developing second cancers general population yet clear whether treatments absence symptoms many clinicians recommend simply monitoring waldenström stated let well patients asymptomatic cases classified two successively premalignant phases igm monoclonal gammopathy undetermined significance smoldering waldenström occasion disease fatal french president georges pompidou died office six years discovery cancer mohammad reza shah pahlavi shah iran also waldenström macroglobulinemia resulted illfated trip united states therapy leading iran hostage treatment started address paraprotein level lymphocytic panel international workshop waldenströms macroglobulinemia agreed criteria initiation therapy recommended starting therapy patients constitutional symptoms recurrent fever night sweats fatigue due anemia weight loss progressive symptomatic lymphadenopathy spleen enlargement anemia due bone marrow infiltration complications hyperviscosity syndrome symptomatic sensorimotor peripheral neuropathy systemic amyloidosis kidney failure symptomatic cryoglobulinemia also suggested indications treatment includes monoclonal antibody rituximab sometimes combination chemotherapeutic drugs chlorambucil cyclophosphamide vincristine corticosteroids prednisone may also used combination plasmapheresis used treat hyperviscosity syndrome removing paraprotein blood although address underlying ibrutinib another agent approved use condition combination treatment ibrutinib rituximab showed significantly higher disease progression free survival rituximab autologous bone marrow transplantation treatment zanubrutinib indicated treatment adults waldenström primary secondary resistance invariably develops salvage therapy considered allogeneic stem cell transplantation induce durable remissions heavily pretreated october total clinical trials waldenström macroglobulinemia excluding transplantation treatments performed previously untreated patients patients relapsed refractory database clinical trials investigating waldenström macroglobulinemia maintained national institutes health patients polymorphic variants alleles associated improved categorical responses rituximabbased current medical treatments result survival longer years part better diagnostic testing means early diagnosis treatments older diagnosis treatments resulted published reports median survival approximately years time currently median survival rare instances waldenström macroglobulinemia progresses multiple international prognostic scoring system waldenströms macroglobulinemia predictive model characterise longterm according model factors predicting reduced risk categories fiveyear survival rates categories corresponding median survival rates international prognostic scoring system waldenströms macroglobulinemia shown also applicable patients rituximabbased treatment additional predictive factor elevated serum lactate dehydrogenase cancers involving lymphocytes cases waldenström rare disorder fewer cases occurring united states annually median age onset years cases occurring late teens notable victims disease include dancerchoreographer gower champion died disease aged former french president georges pompidou waldenström macroglobulinemia first described jan g waldenström two patients bleeding nose mouth anemia decreased levels fibrinogen blood hypofibrinogenemia swollen lymph nodes neoplastic plasma cells bone marrow increased viscosity blood due increased levels class heavy proteins called time waldenström macroglobulinemia considered related multiple myeloma presence monoclonal gammopathy infiltration bone marrow organs plasmacytoid lymphocytes new world health organization classification however places waldenström macroglobulinemia category lymphoplasmacytic lymphomas subcategory indolent lowgrade nonhodgkin since significant advances understanding treatment waldenström aggressive sézary disease